Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Phase 1b data show low rate of differentiation syndrome and no cardiac safety signal of QTc prolongation MILAN, Italy — Johnson & Johnson (NYSE: JNJ) today announced...
treatment News
PASADENA, Calif. — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical...
Boston, Mass. – Sickle cell disease, while rare, is the most common inherited blood disorder and affects over 100,000 people in the United States, more than 90% of whom are Black according to the Centers for Disease Control and Prevention. Although a medication called hydroxyurea can alleviate pain and lower...
Boston, MA – A significant survival improvement for adults with newly diagnosed BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia is published today by the New England Journal of Medicine. The practice-changing finding is from the randomized phase 3 study E1910 (NCT02003222), which evaluated blinatumomab immunotherapy in patients who were in remission...
BUFFALO, NY – A new editorial was published in Oncoscience’s Volume 12 on January 14, 2025, titled, “Pomalidomide improved immune profiles in myeloma.” The editorial by researchers Hannah Seah, Vaishnavi Reddy Bade, Lakshmi Bhavani Potluri, Srikanth Talluri, and Rao H. Prabhala from Dana-Farber Cancer Institute, VA Boston Healthcare System, and...
FRIENDSWOOD, Texas — Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced the publication of a new study in The Journal of Clinical and Aesthetic Dermatology (JCAD) which found that using its DecisionDx-SCC test to guide ART decisions for patients with SCC could...
BERLIN — Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia),...
TORONTO, Ontario – Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced the publication of a retrospective analysis of patients living with amyotrophic lateral sclerosis (ALS) in Muscle and Nerve.1 The analysis evaluated patients taking RADICAVA® Oral Suspension (edaravone) compared with Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) 2 historical...
HEIDELBERG, Germany – BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration between both institutions and researchers at the German Cancer Research Center (DKFZ), the University of Heidelberg,...
Chicago, Ill. – The lab of Yongchao C. Ma, PhD, at Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago uncovered a novel mechanism that leads to motor neuron degeneration in spinal muscular atrophy (SMA). This discovery offers a new target for treatment that...